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Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver accounting for 7% of all cancers worldwide.
Most cases ofHCCdevelopwithin an established background of chronic liver disease. For that reason, liver resection is only possible
in selected patients. Liver transplantation has become the treatment of choice in patients with HCC, end-stage liver disease, and
significant portal hypertension. Shortage of organ donors has resulted in overall increase of waiting list time with increased risk of
dropout due to tumor progression. Neoadjuvant therapies have emerged as an alternative to control tumor growth in patients while
waiting.The aimof this study is to review the literature on the role of bridging therapy and downstaging prior to liver transplantation
in patients with HCC.We are also presenting our single-center experience of 96 patients undergoing transplantation for HCC with
and without bridging therapy.
1. Introduction
Hepatocellular carcinoma (HCC) is the most common pri-
mary malignancy of the liver, the sixth most common cancer
(749,000 new cases each year), and the third cause of cancer-
related death worldwide [1].
In the western world, most cases of HCC develop within
an established background of chronic liver disease and portal
hypertension (70%–90% of all patients). Liver resection is
only possible in selected cases due to the high incidence
of morbidity and mortality in patients with cirrhosis and
elevated portal pressures. Liver transplantation (LT) has
become the treatment of choice for patients with HCC and
end-stage liver disease, as it has the advantage of eradicating
the tumor and the premalignant cirrhotic liver. Recurrence
after LT ranges from 8% to 15% when a specific criterion for
selection of patients is used. Surgical resection and ablation
therapies have been associated with much higher rates of
recurrence [2].
After Milan criteria were established (single nodule less
than 5 cm or 3 nodules less than 3 cm), excellent results
have been reported with survival in the range of 60%–70%
at 5 years [3, 4]. Nonetheless, shortage of organ donors is
increasing thewaiting time and consequently leading to 30%–
40% dropout per year because of tumor progression [5].
Therefore, the practice of treating HCC patients with
locoregional therapies before LT, as they are waiting to be
transplanted, has become standard in most centers [6].
We reviewed the literature on the use of locoregional
therapies prior to liver transplantation and analyzed patients
undergoing transplantation for HCC in our institution with
emphasis on bridging therapy.
2. Locoregional Therapies as a Bridge to
Liver Transplantation
Locoregional therapies play a major role in the current thera-
peutic management of HCC. They encompass a broad range
of modalities including radiofrequency ablation (RFA), per-
cutaneous ethanol injection (PEI), transarterial chemoem-
bolization (TACE), liver resection, and microwave ablation
[7, 8].
The most significant problem in patients with HCC on
the waiting list is the possibility of tumor progression. For
this reason, most centers started to use locoregional or
neoadjuvant therapies to control tumor growth in patients
while waiting. Although bridging therapies using ablation,
TACE, resection, or combination treatments have been used
by different transplant centers worldwide, the real impact
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and indication of any type of neoadjuvant treatments are
still in debate. Some authors propose that patients with HCC
waiting for more than 3 to 6 months should be treated [9, 10].
Various studies have suggested that treatment of HCC prior
to LT in patients with a waiting time less than 6 months is
not associated with an impact in patient survival or tumor
recurrence and raises the question of cost effectiveness of
treatment [11]. The overall risk of dropout in patients with
diagnosis of HCC waiting for liver transplantation has been
reported in the range of 15% to 30% at one year. New studies
have reported that a lower incidence of dropout in the range
of 0% to 25% may be related to the use of neoadjuvant
therapies.
However, locoregional or neoadjuvant treatments prior
to liver transplantation have been used to reduce tumor
burden if patients are considered to be outside criteria
for transplantation in a strategy called downstaging. The
group from Paris, France, at L’Hopital Paul Brousse, initially
recommended this strategy in 1997. They observed higher
rates of survival in TACE responders than in nonresponders
in an analysis of patients with more than three nodules
or nodules greater than 3 cm [12]. LT was then performed
only in patients that fulfilled Milan criteria after treatment.
Furthermore, several prospective studies have reported good
patient survival compared to patients undergoing LT without
prior intervention.
2.1. Ablation. The use of radiofrequency ablation (RFA) for
the treatment of liver tumors started in the early 1990s both
in Europe and in the USA [13]. Radiofrequency ablation
(RFA) is a form of locoregional therapy that utilizes a high-
frequency alternating current using a probe inserted into the
tumor.
The radiofrequency waves are converted into thermal
energy within the conducting tissue, destroying the tumor
[14]. Early experiences reported high risk of seeding, making
RFA not an appealing treatment in patients while waiting
to be transplanted. However, in the last few years, a well-
conducted cohort study demonstrated that seeding is a rare
event [7].
Percutaneous ethanol injection was used for several years
in Asia and then in Europe and the USA to treat HCC with
excellent results in patientswith small tumors andwas usually
limited to less than 3-4 lesions. PEIwas used formany years as
treatment and more recently as bridging therapy in patients
waiting for liver transplantation.
Other authors previously published that PEI can produce
similar amounts of tumor necrosis although it requires a
significant additional number of sessions compared to RFA.
For that reason, most centers in the USA use RFA as the pre-
ferred method of ablative therapy to treat or as neoadjuvant
treatment in patients with HCC. Llovet et al. demonstrated
in a Markov model that ablation in patients awaiting liver
transplantation had a possible gain in life expectancy and cost
per year of life saved.
Several studies [7, 15–19] validated the efficacy of RFA
as the most promising therapy for bridging patients to
transplantation. Patients with single nodules treated with
RFA showed drop-out rates ranging from 0% to 21%,
while historical nontreated controls showed drop-out rates at
1 year of 30% [20].
RFA has few theoretical advantages over TACE. It has less
posttreatment discomfort and simple percutaneous access,
and it can be applied in patients withmild-moderate to severe
liver dysfunction [21].
Ethanol injection could still be recommended in cases
where radiofrequency ablation is not technically feasible such
as lesions located close to large vascular structures where heat
sinking effect can be observed (around 10%–15%) [22].
Other therapies such as microwave ablation have been
used in some centers, but they are still under investigation.
Irreversible electroporation is another ablation technique
that has been used in patients with tumors abutting major
vascular structures where heat sink and collateral damage
must be avoided. The role of this technique as neoadjuvant
treatment in HCC patients awaiting transplantation is still to
be determined [23].
2.2. Transarterial Chemoembolization. TACE combines
two different therapeutic approaches. First, application of
chemotherapeutic agents is usually mixed with lipiodol as
a vehicle into the feeding vessels of the tumor. Lipiodol
is an oily contrast used for lymphographic studies and is
selectively retained within the tumor, raising the exposure
of neoplastic cells to chemotherapy. Second, the feeding
artery is occluded by microparticles inducing ischemia and a
prolonged exposure to the chemotherapeutic agent. Hepatic
artery obstruction is usually achieved by Gelfoam particles,
but not polyvinyl alcohol (PVA), starch microspheres,
metallic coils, and autologous blood clots [24]. Drug-eluting
beads (DEB) are a novel system consisting of PVA beads
(500–700𝜇m) that are specifically designed to release
chemotherapy at a slow rate.
Survival of patients with advanced HCC not suitable for
radical therapies treated with TACE is improved compared
with best supportive care [25]. Side effects range from
the postembolization syndrome up to hepatic insufficiency,
which is very rare. The main purpose of TACE as a bridge to
transplantation is to reach local tumor control until a donor
organ becomes available [26].
TACE is the preferred single-treatment modality in
downstaging protocols, especially for multifocal tumors [10].
But combined modalities of TACE, RFA, PEI, and resection
seem to downstage patientsmore effectively than TACE alone
[27].
TACE is the most commonly used form of neoadjuvant
therapy, alone or in combination with ablation/resection, in
patients listed for LT or included in a programof downstaging
[6].
The use of external beam radiation therapy in HCC treat-
ment has been limited by the low radiation tolerance of the
nontumoral cirrhotic liver. Transarterial radioembolization
(TARE) instead has been recently used in the management
of HCC not suitable for curative treatment with similar
indications as those of TACE. Radioembolization consists
of infusion of radioactive substances including microspheres
containing yttrium-90 (Y90), iodine-131-iodized oil, or sim-
ilar agents into the hepatic artery [9]. It represents an
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interesting alternative, as it appears to induce a more efficient
decrease in tumor size, with a shorter time to response
(4.2 versus 10.9 months) [28]. In addition, TARE could be
performed in cases of portal vein thrombosis, a relative
contraindication to TACE [29].
There are no randomized control trials available to assess
the real place of this treatment modality in HCC patients or
as a bridge to transplantation.
2.3. Resection. Surgery is the mainstay of HCC treatment.
Resection and transplantation achieve the best overall out-
comes in well-selected candidates (5-year survival of 60%–
80%) and compete as the first options in patients with early
tumors.
Resection is the first-line treatment option for patients
with solitary tumors and very well-preserved liver function,
defined as normal bilirubin with either hepatic venous
pressure gradient≤10mmHor platelet count≥100,000.While
selected patientswith cirrhosis are best treatedwith resection,
patients with ESLD and portal hypertension are at increased
risk of morbidity and mortality compared to noncirrhotic
counterparts. For these reasons, only 20%–30% of patients
with cirrhosis, portal hypertension, and HCC are candidates
for resection. Selection of the ideal candidate requires an
adequate assessment of the liver functional reserve, tumor
extension, and risk of postoperative complications and mor-
tality.
Several different systems have been used to try to address
risk of morbidity and mortality after resection in patients
with portal hypertension and cirrhosis. The Child-Pugh
classification system initially permitted assessment of liver
function. Nowadays, more sophisticated measurements such
as indocyanine green retention rate at 15min (ICG15) [30]
and hepatic venous pressure gradient (HVPG) as direct
measurements of relevant portal hypertension are utilized
[31, 32]. Low platelet count has been confirmed as a strong
independent predictor of mortality in patients with HCC and
cirrhosis [22, 33].
Resection can be used as a therapy for HCC prior to LT
in different settings. Initially, resection can be used as a first-
line treatment for patients with small HCC and preserved
liver function. Also resection could help refine the selection
process for LT according to detailed pathological examina-
tion of the tumor and the surrounding liver parenchyma.
It could help in selection of candidates for LT in patients
with tumors slightly outside the Milan criteria but with
histological features of good prognosis or in denying LT
in patients within the Milan criteria but with histological
features of poor prognosis such as undetected macrovascular
invasion.
Several groups considered surgical resection as one of
the bridging treatment modalities prior to LT. Other groups
consider liver resection as one of the options for downstaging
patients with tumors outside the transplantation criteria [34].
Tumor recurrence represents one of the major difficulties
after resection. The pattern of recurrence influences subse-
quent treatment allocation and outcomes. In these instances,
the patients could be reassessed, staged, and retreated accord-
ingly.
3. Downstaging
The role of downstaging HCC patients prior to LT is not
very clear. There are several centers in the USA and Europe
trying to use different types of neoadjuvant therapy to treat
HCC to decrease tumor burden to fulfill usually Milan
criteria and then perform liver transplantation. The type of
therapy that should be used and the upper limit of tumor
size that should be downstaged are not clear. Some authors
have recommended putting the candidate on hold until
downstaging by local ablation and/or chemoembolization is
achieved and maintained (disease stability) for a period of at
least three months [22]. However, the real waiting time after
successful downstaging is not clear.
There is not a single randomized control trial or a
large cohort study available on patients consistently treated
and properly followed. Various prospective small studies
suggested that downstaging tumors to reach Milan criteria
using RFA and/or TACE achieves 5-year survival rates similar
to those within the conventional criteria after LT.
Ravaioli et al. presented a prospective study providing val-
idation of a downstaging protocol, in which patients, initially
excluded by the conventional transplant criteria, undergoing
successful downstaging obtained satisfactory survival after
LT [35]. Still efficacy of downstaging in patients exceeding
conventional criteria is strictly related to tumor size and
number at presentation.The bigger the tumor bulk, the lower
the efficacy of downstaging in terms of tumor response [10].
Considering the existing information, downstaging of
patients beyond Milan criteria still remains controversial,
and criteria for selecting candidates are not well established.
Chapman et al. considered most patients beyond Milan
criteria and did not exclude a priori any patients. This group
reported that 17 out of 76 patients were transplanted after
successful downstaging.They reported comparable outcomes
in these 17 patients to those in patients within Milan criteria
[36]. Yao et al. restricted downstaging eligibility criteria to
one lesion >5 cm and up to 8 cm; 2 to 3 tumors with at
least one lesion >3 cm but not exceeding 5 cm, with total
tumor diameter up to 8 cm; or 4 to 5 lesions with none >3 cm
with total tumor diameter less than 8 cm. Using these criteria
as an upper limit for downstaging, 57.4% (35/61) of their
patients were successfully downstaged and transplanted [37].
Ravaioli et al. prospectively analyzed patients with a single
HCC5 cm to 6 cm, 2 lesions≤5 cm, or less than 6HCC lesions
≤4 cm and sum diameter ≤12 cm, and they achieved a 67%
transplantation rate (32/48 patients). They achieved similar
outcomes in patients treated versus thosewithin conventional
Milan criteria [35].
4. Our Experience
In the Transplant Center at the University of Kentucky,
the strategy for management of HCC has evolved with a
multimodality algorithm approach similar to that adopted in
other centers [38].
We retrospectively analyzed our experience of 96 con-
secutive patients undergoing transplantation for HCC from
September 1999 to September 2011. Of the 96 patients, 78were
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Table 1: Patient demographics.
Patient demographics
Age 56 (36–72)
Sex
Male 78 81.30%
Female 18 18.70%
Incidental 31 32.30%
ALD 40 41.70%
HCV 48 50%
BT 19 29.20%
Size of greater lesion (mean) 2.3 (0.7–7.6 cm)
Single 51 54.40%
Vascular invasion 22 22.90%
Alcoholic liver disease (ALD); hepatitis C cirrhosis (HCV); bridging therapy
(BT).
males (81.3%). As expected, hepatitis C (HCV) was the most
common indication in this group (48 patients, 50%), followed
by alcoholic liver disease (40 patients, 41.7%). Among the
96 patients who underwent LT, 31 patients were identified as
having incidentalHCCon the explanted livers, undetected on
preoperative imaging (Table 1).
A total of 49 patients (54.4%) had single lesions.Themean
diameter of the greatest lesion was 2.3 cm, ranging from 0.7
to 7.6 cm. Vascular invasion was found in 22 patients (22.9%).
Analysis of survival was performed using the Kaplan-
Meier method. For intention-to-treat survival, all 96 patients
were followed up from the time of listing to death or last
followup. Overall survival rates of 89.2%, 74.1%, and 62.1%
at one, three, and five years were observed, respectively. As
expected, patients with vascular invasion had significantly
worse survival compared to those patients with tumors
without vascular invasion (𝑃 < 0.005). Rates at one, three,
and five years for patients without vascular invasion were
90.9%, 77.6%, and 66.1%, respectively, while for patients with
vascular invasion survival was considerably lower; 71.6%,
61.7%, and 46.3% (Figures 1 and 2).
We compared patient characteristics in individuals
undergoing bridging therapywith thosewithout preoperative
treatment (Table 2). Patients characteristics were similar in
both groups other than tumor size greater than 3 cm that was
more common in patients in the BT group (𝑃 < 0.005).
Nineteen liver transplant candidates representing 29.2%
of known HCC cases were treated with locoregional ther-
apies (Table 2). Of those patients undergoing neoadjuvant
treatments, 10 were treated with RFA (15.4%), 8 with TACE
(12.3%), 1 with resection (1.5%), and 1 with RFA/TACE
combination (1.5%).
Recurrence was seen in 13 patients representing 13.2% or
our cases transplanted forHCC. Survival and recurrence rates
were similar in treated patients versus nontreated individuals
(𝑃 = ns).
5. Discussion
Liver transplantation represents the best curative option for
HCC and cirrhosis as it has the advantage of removing the
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Figure 1: This graphic shows survival among patients undergoing
LT with and without vascular invasion. Survival is significantly
better in those patients transplanted without vascular invasion (𝑃 <
0.05).
tumor and treating the underlying disease. Despite that, HCC
can progress significantly in patients awaiting LT. It has been
reported an approximate doubling time for these cancers
of around 6 months [39]. As a consequence, tumors can
grow beyond conventional criteria, increasing the possibility
of microvascular invasion and occult metastasis and further
worsening the patient condition.
Recent advances in imaging techniques, especially with
the use of liver-specific contrastMRI, aremaking diagnosis of
HCC and quantification of the amount of disease more accu-
rate. Gadolinium-ethoxybenzyl-diethylenetriamine pentaa-
cetic acid (Gd-EOB-DTPA) is a liver-specific magnetic res-
onance imaging contrast agent that has up to 50% hepatobil-
iary excretion in the normal liver. After intravenous injection,
Gd-EOB-DTPA distributes into the vascular and extravascu-
lar spaces during the arterial, portal venous and late dynamic
phases and then progressively into the hepatocytes and bile
ducts during the hepatobiliary phase.The role of gadolinium-
ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced
magnetic resonance imaging (EOB-MRI) in themanagement
of HCC is still to be determined. However, most centers are
now using EOVIST when regular dynamic CT/MRI images
do not show conclusive findings.
Selection criteria for liver transplantation in HCC
patients are still controversial [22, 40–43]. Although initial
International Journal of Hepatology 5
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Figure 2:This graphic demonstrates survival amongpatients under-
going LTwith andwithout bridging treatment. Similar survival rates
were observed in patients transplanted with and without BT (𝑃 =
ns).
Table 2: Comparison of patients, characteristics.
Comparison of patients’ characteristics
Bridging therapy versus nonbridging therapy
BT Non-BT Sig
Age 59.4 55.9 0.47
Sex (male) 16 58 0.46
AFP 168 160 0.98
MELD 13 16 0.86
Waiting time 59.5 152.1 0.09
Vascular invasion 5 15 0.45
Multiple 7 33 0.32
Size > 3 cm 7 11 0.04∗
HCV 11 36 0.26
∗Statistically significant (𝑃 < 0.05).
Bridging therapy (BT); alpha-fetoprotein (AFP); hepatitis C cirrhosis
(HCV).
LT results in nonselected patients with HCC were discour-
aging, subsequent series proved that better results could
be achieved by employing defined selection criteria [44].
The criteria proposed by Mazzaferro et al. in 1996 are used
as a basic stratification tool by numerous transplantation
centers worldwide [2]. Using these criteria, a patient with
a single tumor measuring 5 cm or less, or three or fewer
nodules each smaller than 3 cm, would be a candidate for LT.
Excellent 5-year survival rates in the range of 60%–70% or
higher have been reported when these criteria are followed.
Subsequently, the University of California at San Francisco
reported 57% survival for patients with HCC who exceeded
Milan criteria but were within the limits of their expanded
criteria, including patients with solitary lesions less than
6.5 cm in size or up to three tumors with the largest not more
than 4.5 cm and a combined tumor diameter of notmore than
8 cm [45]. The TNM criteria by Marsh et al. at the University
of Pittsburgh are based on HCC characteristics including
microvascular or macrovascular invasion, lobar distribution,
tumor size, and lymph node involvement, and they seemed to
provide a more clear-cut discrimination with respect to post-
OLT survival for each TNM tumor stage (I to IV) [46].
Yao et al. compared the previous three proposed criteria
and supported a modest expansion of the tumor size limits of
the Milan criteria (the UCSF criteria) while still preserving
acceptable survival after OLT. The expanded criteria offered
the benefits of OLT to about 20% of our patients who
would have otherwise been excluded from OLT under the
more restrictive Milan criteria.The UCSF criteria also confer
an advantage over the Pittsburgh criteria, which require
information on microvascular invasion that is difficult to
ascertain preoperatively without the attendant risks of biopsy
[47].
Candidacy is now decided based on size and number
of lesions (Milan, UCSF criteria, etc.). However, there are
other important predictors of recurrence and patient sur-
vival that have not been included in the current selection
system such as AFP/AFPL3% levels, tumor differentiation,
and microvascular invasion. AFP is the most widely tested
biomarker in HCC [22]. Lens culinaris agglutinin-reactive
AFP (AFP-L3) is an isoform of AFP that is very specific
for screening and diagnosis of HCC in the background of
cirrhosis or hepatitis.However, the clinical usefulness ofAFP-
L3 in HCC has been inconsistent. Unfortunately, there has
been large heterogeneity on the results of multiple studies
when assessing AFP-L3% and AFP in the same population
[48].
The relationship between AFP levels and tumor burden
has been determined in HCC patients. Our group reported
that tumor size and AFPwere strongly related to the presence
of microvascular invasion (MVI) on the explanted liver.
AFP in conjunction with other markers such as des-gamma-
carboxyprothrombin and AFP-L3 has been associated with
tumor burden as well [49]. Because of the relationship with
tumor burden and outcomes, several centers are now using
highly elevated levels of AFP to rule out patients for liver
transplantation. In 2012, Duvoux et al. published that levels
of AFP greater than 1000U/dL are associated with high risk
of recurrence and suggested that AFP should be incorporated
to the Milan criteria in order to select patients for liver
transplantation [50].
Based on UNOS data, the 3 most common indications
for liver transplantation in the USA are hepatitis C, alcoholic
liver disease, and hepatocellular carcinoma. Interestingly, in
2010, HCC is already the second most common indication
for transplantation, second only to hepatitis C. A significant
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amount of patients with HCC have concomitant HCV infec-
tion which could compromise outcomes in this subgroup of
patients.
Reinfection of the liver graft by HCV is constant, and
the natural history of HCV recurrence is accelerated com-
pared with nontransplanted patients when serumHCV RNA
remains detectable at LT. Approximately 20% to 30% of
patients will develop cirrhosis within 5 years after LT.
The best strategy to prevent recurrence of HCV is to
eradicate HCV infection prior to LT. Treatment before the
development of injury to the graft in the early phase is
currently not recommended because studies have shown that
it is difficult to initiate antiviral therapy with IFN during
the postoperative period and that it has a poor efficacy
with remarkable side effects such as bacterial infections,
hematological toxicity, and rejections, which lead to dose
reduction or discontinuation of treatment.
HCV therapy should be initiated in the presence of severe
and rapid progression of fibrosis with a higher risk of graft
loss, especially in the setting of cholestatic hepatitis. Current
regimens included antiviral therapy with PEG-IFN/RBV,
and several studies have shown that a sustained virological
response is achieved in 8%–45%. Three different systematic
reviews of PEG-IFN/RBV after LT showed that the SVR rate
is around 30% [51–53]. The duration of therapy is usually
48 weeks, and therapy is influence by several factors which
influences the prognosis before and during therapy such as
viral genotype, donor age, baseline viral load, IL28B donor
and recipient, absence of prior antiviral therapy, severity of
baseline fibrosis, adherence to therapy, duration of therapy,
rapid virological response, and early virological response.
Due to the development of new drugs for the treatment
of HCV infection, most experts believe that treatment of
HCV recurrence after LT will change in the next few years.
The role of triple therapy using PEG-IFN/RBV plus protease
inhibitors is not clear. Verna EC et al. recently published
the results of a multicenter study using triple therapy with
Telaprevir in HCV recurrence after LT reporting increased
sustained viral response rates exceeding those with standard
treatment with PEG-IFN/RBV alone [54].These results must
be balanced with high rates of adverse events including
increased risk of readmissions, kidney dysfunction, and
death. There are now other protocols under investigation
in patients with cirrhosis including noninterferon regimens.
The role of these treatment combinations in the LT setting is
still to be determined.
The timing and adequacy of HCC treatment before liver
transplantation to control the disease are unclear. New min-
imally invasive strategies are being implemented to decrease
tumor progression in patients with diagnosis of HCC while
waiting to be transplanted.
The appropriate treatment alternative that should be used
as neoadjuvant therapy prior to LT such as liver resec-
tion, radiofrequency ablation (RFA), transarterial chemoem-
bolization (TACE), or combination remains under debate.
Considering the strength and existing evidence, it is
recommended to treat patients waiting for transplant with
local ablation and/or chemoembolization when waiting time
is estimated to exceed 6months. Furthermore, several cohort
studies and a preliminary analysis of large registries sug-
gest that bridging strategies with locoregional therapy are
likely to be beneficial for patients waiting for 6 months or
longer. The recommendation of bridging therapy is more
important in UNOS T2 HCC patients to decrease dropout
rates and achieve good posttransplant outcomes [55, 56].
A Markov-based cost-effectiveness analysis by Llovet et al.
pointed out the benefits of neoadjuvant therapies when
waiting time exceeded 6 months [5]. In our center, the
decision to use bridging therapy is done on an individual
basis by a multidisciplinary team integrated by hepatologist,
radiologist, interventional radiologists, oncologist, radiation
oncologists, and transplant surgeons.We usually recommend
TACE and/or RFA in patients with UNOS stage 2 HCC prior
to LT if 6months or longer waiting time is expected in rapidly
growing tumors or in large lesions close to the upper size
limits of the Milan criteria.
Based on the International Consensus Conference held in
December 2010 in Zurich, Switzerland, specific recommen-
dations regarding downstaging cannot be properly made due
to the lack of evidence, and further research is needed [22].
Although adjuvant therapy is currently used in most
centers in the USA and Europe, further investigation is
needed to determine the efficacy and timing of neoadjuvant
treatment modalities for HCC in patients awaiting liver
transplantation.
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